BHST / BioHarvest Sciences Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission file number: 001-42

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

BioHarvest Sciences to Host a Virtual Investor Webinar on September 10, 2025 at 1:00 PM ET

News Release dated September 2, 2025 BioHarvest Sciences to Host a Virtual Investor Webinar on September 10, 2025 at 1:00 PM ET Rehovot, Israel - September 2, 2025 - BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOHARVEST SCIENCES INC. (Exact name of Registrant as specified in its charter) Not applicable (Translation of Re

Registration Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

BUSINESS CORPORATIONS ACT AMENDED ARTICLES BIOHARVEST SCIENCES INC. Table of Contents

Articles, as amended on June 26, 2025 Incorporation No. BC0967987 BUSINESS CORPORATIONS ACT AMENDED ARTICLES OF BIOHARVEST SCIENCES INC. Table of Contents Part 1 – Interpretation2 Part 2 – Shares and Share certificates3 Part 3 – Issue of Shares4 Part 4 – Share Transfers4 Part 5 – Acquisition of Shares5 Part 6 – Borrowing Powers5 Part 7 – General Meetings5 Part 8 – Proceedings at Meetings of Shareh

Security Type

Calculation of Filing Fee Tables F-3 BIOHARVEST SCIENCES INC. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward In

BioHarvest Sciences Inc. 1140-625 Howe Street Vancouver, British Columbia V6C 2T6, Canada (604) 689-5722

Delaying Amendment BioHarvest Sciences Inc. 1140-625 Howe Street Vancouver, British Columbia V6C 2T6, Canada (604) 689-5722 August 28, 2025 VIA EDGAR United Stated Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re:Delaying Amendment for BioHarvest Sciences Inc. Registration Statement on Form S-3 File No. 333-289908 Ladies and Gentlemen: Reference is made to the Registra

FORM 51-102F3 MATERIAL CHANGE REPORT

Material Change Report dated August 14, 2025 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission file number: 001-42389

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

BioHarvest Sciences Amended Insider Trading Policy

News Release dated August 13, 2025 BioHarvest Sciences Amended Insider Trading Policy Rehovot, Israel – August 13, 2025 –BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission file number: 001-42389

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

BioHarvest Sciences Inc. Management’s Discussion and Analysis For the three and six months ended June 30, 2025 (Expressed in U.S. dollars)

Management’s Discussion and Analysis BioHarvest Sciences Inc. Management’s Discussion and Analysis For the three and six months ended June 30, 2025 (Expressed in U.S. dollars) INTRODUCTION The following Management’s Discussion and Analysis (“MD&A”) for BioHarvest Sciences Inc., together with its wholly owned subsidiaries (“BioHarvest Sciences” or “the Company”) prepared as of August 11, 2025, been

Form 52-109F2 Certification of Interim Filings Full Certificate

Certificate - CFO This is an unofficial consolidation of Form 52-109F2 Certification of Interim Filings Full Certificate reflecting amendments made effective January 1, 2011 in connection with Canada’s changeover to IFRS.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission file number: 001-42389

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

BioHarvest Sciences Reports Second Quarter 2025 Financial Results Robust 41% Year-Over-Year Revenue Growth, Driven by Strong Core Capsule and New Product Sales

News Release dated August 11, 2025 BioHarvest Sciences Reports Second Quarter 2025 Financial Results Robust 41% Year-Over-Year Revenue Growth, Driven by Strong Core Capsule and New Product Sales Rehovot, Israel – August 11, 2025 - BioHarvest Sciences Inc.

BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three and Six Months Ended June 30, 2025 Expressed in U.S. dollars in thousands BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial

Unaudited Interim Condensed Consolidated Financial Statements BioHarvest Sciences Inc.

Form 52-109F2 Certification of Interim Filings Full Certificate

Certificate - CEO This is an unofficial consolidation of Form 52-109F2 Certification of Interim Filings Full Certificate reflecting amendments made effective January 1, 2011 in connection with Canada’s changeover to IFRS.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission file number: 001-42389

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission file number: 001-42389

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

BioHarvest Sciences to Host Second Quarter 2025 Earnings Call on August 11 at 8:00 a.m. Eastern Time

News Release dated August 4, 2025 BioHarvest Sciences to Host Second Quarter 2025 Earnings Call on August 11 at 8:00 a.

Calculation of Filing Fee Tables Form S-8 (Form Type) BioHarvest Sciences Inc. (Exact Name of Registrant as Specified in its Charter) Table 1. Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(3)

Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) BioHarvest Sciences Inc.

BioHarvest Sciences to Present at Canaccord Genuity 45th Annual Growth Conference on August 12-14, 2025

News Release dated July 23, 2025 BioHarvest Sciences to Present at Canaccord Genuity 45th Annual Growth Conference on August 12-14, 2025 Rehovot, Israel – July 23, 2025 – BioHarvest Sciences Inc.

BIOHARVEST SCIENCES INC. 2025 EQUITY INCENTIVE PLAN

2025 Equity Incentive Plan BIOHARVEST SCIENCES INC. 2025 EQUITY INCENTIVE PLAN 1. PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIOHARVEST SCIENCES INC. (Exact name of registrant as specified in its charter) BRITISH COLUMBIA, CANADA Not Appl

Registration Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission file number: 001-42389 B

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission file number: 001-42389 B

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

FORM 51-102F3 MATERIAL CHANGE REPORT

FORM 51-102F3 MATERIAL CHANGE REPORT Item 1.Name and Address of Company BIOHARVEST SCIENCES INC. Suite 1140 – 625 Howe Street Vancouver, BC, V6C 2T6 (the “Company” or “BioHarvest”) Item 2.Date of Material Change June 26, 2025. Item 3.News Release The news release (the “News Release”) was issued on July 3, 2025 and disseminated by Stockwatch. Item 4.Summary of Material Change The Company announced

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission file number: 001-42389 B

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

BioHarvest Announces Results of Annual General and Special Meeting

News Release dated July 2, 2025 Nasdaq: BHST – FSE:8MV BioHarvest Announces Results of Annual General and Special Meeting Rehovot, Israel – July 2, 2025 - BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission file number: 001-42389 B

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

BIOHARVEST SCIENCES INC.

BIOHARVEST SCIENCES INC. INTERIM FINANCIAL STATEMENTS ANNUAL FINANCIAL STATEMENTS ☐Mark this box if you would like to receive Interim Financial Statements by mail. ☐Mark this box if you would like to receive Annual Financial Statements by mail. Financial Statements Request Form Under securities regulations, a reporting issuer must send annually a form to holders to request the Interim Financial St

BIOHARVEST SCIENCES INC. 1140-625 Howe Street Vancouver, BC V6C 2T6 Telephone: (604) 685-4745 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING

BIOHARVEST SCIENCES INC. 1140-625 Howe Street Vancouver, BC V6C 2T6 Telephone: (604) 685-4745 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING TO THE SHAREHOLDERS: NOTICE IS HEREBY GIVEN that the annual general and special meeting (the “Meeting”) of BioHarvest Sciences Inc. (the “Company”) will be held at Suite 704, 595 Howe Street, Vancouver, B.C. V6C 2T5 on June 26, 2025, at 10:00 a.m. (Vancouver ti

EX-99.6

BIOHARVEST SCIENCES INC. 1140-625 Howe Street Vancouver, BC V6C 2T6 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 26, 2025 INFORMATION CIRCULAR May 23, 2025

BIOHARVEST SCIENCES INC. 1140-625 Howe Street Vancouver, BC V6C 2T6 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 26, 2025 AND INFORMATION CIRCULAR May 23, 2025 This document requires immediate attention. If you are in doubt as to how to deal with the documents or matters referred to in this Information Circular, you should immediately contact your advisor. BIOHAR

FORM OF PROXY Annual General & Special Meeting of the Common Shareholders to be held on Thursday, June 26, 2025 (the “Meeting”)

NATIONAL SECURITIES ADMINISTRATORS LTD. 702 – 777 Hornby Street Vancouver, BC V6Z 1S4, Canada BioHarvest Sciences Inc. Security Class: Common Shares FORM OF PROXY Annual General & Special Meeting of the Common Shareholders to be held on Thursday, June 26, 2025 (the “Meeting”) This Form of Proxy is solicited by and on behalf of the management of BioHarvest Sciences Inc. (the “Company”) Notes to pro

EX-99.7

1

NATIONAL SECURITIES ADMINISTRATORS LTD. 702 – 777 Hornby Street Vancouver, BC, V6Z 1S4 [email protected] www.transferagent.ca BioHarvest Sciences Inc. Via SEDAR+ April 25, 2025 TO ALL APPLICABLE REGULATORS AND EXCHANGES RE: BioHarvest Sciences Inc. (the “Issuer”) Notice of Meeting and Record Dates We advise the following with respect to the Issuer’s upcoming Meeting of Security Holders: 1 Meet

BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles

BioHarvest Launches Informed Sport-Certified VINIA DailyChews 2X Formula for Athletes and People with Active Lifestyles Rehovot, Israel – June 4, 2025 - BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission file number: 001-42389 B

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-42389 BI

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound First CDMO Project to Utilize In-house AI Tools for Discovery of Plant Cell Targets for the Botanical Synthesis Process

BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound First CDMO Project to Utilize In-house AI Tools for Discovery of Plant Cell Targets for the Botanical Synthesis Process Rehovot, Israel - May 21, 2025 - BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-42389 BI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

BioHarvest Sciences Reports First Quarter 2025 Financial Results First Quarter Revenues Grew 47% to $7.9 Million, Exceeding Management Guidance

BioHarvest Sciences Reports First Quarter 2025 Financial Results First Quarter Revenues Grew 47% to $7.

Form 52-109F2 Certification of Interim Filings Full Certificate

This is an unofficial consolidation of Form 52-109F2 Certification of Interim Filings Full Certificate reflecting amendments made effective January 1, 2011 in connection with Canada’s changeover to IFRS.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-42389 BI

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

Form 52-109F2 Certification of Interim Filings Full Certificate

This is an unofficial consolidation of Form 52-109F2 Certification of Interim Filings Full Certificate reflecting amendments made effective January 1, 2011 in connection with Canada’s changeover to IFRS.

BioHarvest Sciences Inc. Management’s Discussion and Analysis For the three months ended March 31, 2025 (Expressed in U.S. dollars)

BioHarvest Sciences Inc. Management’s Discussion and Analysis For the three months ended March 31, 2025 (Expressed in U.S. dollars) INTRODUCTION The following Management's Discussion and Analysis (”MD&A”) for BioHarvest Sciences Inc., together with its wholly owned subsidiaries ("BioHarvest Sciences” or “the Company”) prepared as of May 15, 2025, been prepared in accordance with International Fina

BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three Months Ended March 31, 2025 Expressed in U.S. dollars in thousands

BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three Months Ended March 31, 2025 Expressed in U.S. dollars in thousands BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three Months Ended March 31, 2025 Expressed in U.S. dollars in thousands TABLE OF CONTENTS Page FINANCIAL STATEMENTS: Unaudited Interim C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-42389 BI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

BioHarvest Announces Completion of Stage 1 Development for CDMO Contract with Nasdaq-Listed Pharmaceutical Company Successful Progression Validates Botanical Synthesis Platform for a Variety of Molecule Types

BioHarvest Announces Completion of Stage 1 Development for CDMO Contract with Nasdaq-Listed Pharmaceutical Company Successful Progression Validates Botanical Synthesis Platform for a Variety of Molecule Types Rehovot, Israel - May 12, 2025 - BioHarvest Sciences Inc.

BioHarvest Sciences to Host First Quarter 2025 Earnings Call on May 15 at 4:30 p.m. Eastern Time

BioHarvest Sciences to Host First Quarter 2025 Earnings Call on May 15 at 4:30 p.m. Eastern Time Rehovot, Israel – BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) (“BioHarvest” or the “Company”), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the first quarter ended March 31, 2025 after market close on Thurs

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-42389 BI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

BioHarvest Sciences Reports Fourth Quarter and Full Year 2024 Financial Results Fourth Quarter Revenues Grew 62% to $7.3 Million, Exceeding Prior Management Guidance, with Full Year Revenues Increasing 99% Year-Over-Year to $25.2 Million CDMO Divisio

BioHarvest Sciences Reports Fourth Quarter and Full Year 2024 Financial Results Fourth Quarter Revenues Grew 62% to $7.

Form 52-109F1 Certification of Annual Filings Full Certificate

Form 52-109F1 Certification of Annual Filings Full Certificate I, Ilan Sobel, the Chief Executive Officer of BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission file number: 001-42389

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

Form 52-109F1 Certification of Annual Filings Full Certificate

Form 52-109F1 Certification of Annual Filings Full Certificate I, Bar Dichter, the Chief Financial Officer of BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission file number: 001-42389

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission file number: 001-42389 BIOHARVEST SCIENCES INC.

SUMMARY IN ENGLISH LEASE AGREEMENT DATED JANUARY 16, 2025 BETWEEN BIOHARVEST ISRAEL LTD. AND SUGART LTD. (IN HEBREW)

Certain portions of this summary have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ENACTED PURSUANT TO SECTION 906 OF THE U.S. SARBANES-OXLEY ACT OF 2002

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ENACTED PURSUANT TO SECTION 906 OF THE U.S. SARBANES-OXLEY ACT OF 2002 In connection with the annual report of BioHarvest Sciences Inc. (the “Company”) on Form 40-F for the financial year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ilan Sobel, the Chief Executive Officer of

BIOHARVEST SCIENCES INC. CODE OF BUSINESS CONDUCT AND ETHICS (Adopted as of September 20, 2024)

BIOHARVEST SCIENCES INC. CODE OF BUSINESS CONDUCT AND ETHICS (Adopted as of September 20, 2024) 1.INTRODUCTION. 1.1The Board of Directors (the “Board”) of BioHarvest Sciences Inc. (the “Company”) has adopted this code of business conduct and ethics (the “Code”), as may be amended from time to time by the Board and which is applicable to all of the Company’s directors, officers and employees to: (a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 40-F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 40-F ☐REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Commission File Number: 001-42389 BIOHARVEST SCIENCES INC.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ENACTED PURSUANT TO SECTION 906 OF THE U.S. SARBANES-OXLEY ACT OF 2002

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ENACTED PURSUANT TO SECTION 906 OF THE U.S. SARBANES-OXLEY ACT OF 2002 In connection with the annual report of BioHarvest Sciences Inc. (the “Company”) on Form 40-F for the financial year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bar Dichter, the Chief Financial Officer of

BIOHARVEST SCIENCES INC. EXECUTIVE COMPENSATION CLAWBACK POLICY (Adopted as of September 20, 2024)

BIOHARVEST SCIENCES INC. EXECUTIVE COMPENSATION CLAWBACK POLICY (Adopted as of September 20, 2024) 1.INTRODUCTION. 1.1The board of directors (the “Board”) of BioHarvest Sciences Inc. (the “Company”) has adopted this executive compensation clawback policy (this “Policy”). This Policy shall supplement any other clawback or compensation recovery policy or policies adopted by the Company or included i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A.Name of issuer or person filing ("Filer"):BioHarvest Sciences Inc. B.(1)This is (check one): ☒An original filing for the Filer. ☐An amended filing for the Filer. (2)Check the following box if you are filing the Form F-X in paper in accordance with Regulatio

ANNUAL INFORMATION FORM BIOHARVEST SCIENCES INC. March 31, 2025 TABLE OF CONTENTS

ANNUAL INFORMATION FORM OF BIOHARVEST SCIENCES INC. March 31, 2025 TABLE OF CONTENTS INTRODUCTORY NOTES1 Date of Information1 Cautionary Statement Regarding Forward-Looking Statements and Information1 Presentation of Information3 CORPORATE STRUCTURE3 Name, Address and Jurisdiction3 Intercorporate Relationships3 GENERAL DEVELOPMENT OF THE BUSINESS4 Three-Year History4 Significant Acquisitions6 BUSI

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the use of our report dated March 31, 2025, relating to the consolidated financial statements of BioHarvest Sciences Inc.

CERTIFICATION REQUIRED BY RULE 13a-14(a) OR RULE 15d-14(a), PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION REQUIRED BY RULE 13a-14(a) OR RULE 15d-14(a), PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ilan Sobel, certify that: 1.

CERTIFICATION REQUIRED BY RULE 13a-14(a) OR RULE 15d-14(a), PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

CERTIFICATION REQUIRED BY RULE 13a-14(a) OR RULE 15d-14(a), PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Bar Dichter, certify that: 1.

BioHarvest Sciences Inc. Management’s Discussion and Analysis For the year ended December 31, 2024 (Expressed in U.S. dollars)

BioHarvest Sciences Inc. Management’s Discussion and Analysis For the year ended December 31, 2024 (Expressed in U.S. dollars) INTRODUCTION The following Management's Discussion and Analysis (”MD&A”) for BioHarvest Sciences Inc., together with its wholly owned subsidiaries ("BioHarvest Sciences” or “the Company”) prepared as of March 31, 2025, has been prepared in accordance with International Fin

BioHarvest Sciences Inc. Consolidated Financial Statements For the Year Ended December 31, 2024 Expressed in U.S. dollars in thousands

BioHarvest Sciences Inc. Consolidated Financial Statements For the Year Ended December 31, 2024 Expressed in U.S. dollars in thousands BioHarvest Sciences Inc. CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2024 TABLE OF CONTENTS Page Report of Independent registered public accounting firm (BDO Ziv Haft; Tel-Aviv, Israel; PCAOB ID#1185) 2 FINANCIAL STATEMENTS: Consolidated Statements of Fina

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission file number: 000-56663

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

BioHarvest Sciences to Host Fourth Quarter and Full Year 2024 Earnings Call on March 31 at 4:30 p.m. Eastern Time

Press Release dated March 17, 2025 BioHarvest Sciences to Host Fourth Quarter and Full Year 2024 Earnings Call on March 31 at 4:30 p.

BioHarvest Sciences to Participate in 37th Annual Roth Conference on March 16-18, 2025

BioHarvest Sciences to Participate in 37th Annual Roth Conference on March 16-18, 2025    Vancouver, British Columbia and Rehovot, Israel – March 6, 2025 - BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission file number: 000-56663

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

BioHarvest In Vitro testing Shows Proprietary Olive Cell Compound Reduces Fat Accumulation in Liver Cells Non-Alcoholic Fatty Liver Disease (NAFLD) Affects 30-40% of U.S. Adults, Driving Significant Market Need for BioHarvest’s Future Olive Cell Prod

BioHarvest In Vitro testing Shows Proprietary Olive Cell Compound Reduces Fat Accumulation in Liver Cells Non-Alcoholic Fatty Liver Disease (NAFLD) Affects 30-40% of U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission file number: 000-56663

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

BioHarvest Announces Sales of Flagship Product VINIA Now Exceed $50 Million USD

BioHarvest Announces Sales of Flagship Product VINIA Now Exceed $50 Million USD    Vancouver, British Columbia and Rehovot, Israel – February 18, 2025 - BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission file number: 000-566

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

FORM 51-102F3 MATERIAL CHANGE REPORT

FORM 51-102F3 MATERIAL CHANGE REPORT Item 1.Name and Address of Company BIOHARVEST SCIENCES INC. Suite 1140 - 625 Howe Street Vancouver, BC, V6C 2T6 (the “Company” or “BioHarvest”) Item 2.Date of Material Change February 14, 2025. Item 3.News Release The news release (the “News Release”) was issued on February 10, 2025 and disseminated by Stockwatch. Item 4.Summary of Material Change The Company a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission file number: 000-566

6-K 1 bhsc6k.htm REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission file number: 000-56663 BIOHARVEST SCIENCES INC. (Exact name of Registrant as specified in its charter) Not applicable (Translation of Registrant’s

BioHarvest Sciences to Present at WeBull Consumer Stocks Webinar on February 18

BioHarvest Sciences to Present at WeBull Consumer Stocks Webinar on February 18 Vancouver, British Columbia and Rehovot, Israel – February 12, 2025 - BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission file number: 000-566

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

BioHarvest Sciences Announces Voluntary Delisting from CSE

BioHarvest Sciences Announces Voluntary Delisting from CSE Vancouver, British Columbia and Rehovot, Israel – February 10, 2025 - BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission file number: 000-566

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission file number: 000-5666

6-K 1 bhsc6k.htm REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission file number: 000-56663 BIOHARVEST SCIENCES INC. (Exact name of Registrant as specified in its charter) Not applicable (Translation of Registrant’s

FORM 51-102F3 MATERIAL CHANGE REPORT

FORM 51-102F3 MATERIAL CHANGE REPORT Item 1.Name and Address of Company BIOHARVEST SCIENCES INC. Suite 1140 - 625 Howe Street Vancouver, BC, V6C 2T6 (the “Company”) Item 2.Date of Material Change January 16, 2025. Item 3.News Release The news release (the “News Release”) was issued on January 22, 2025 and disseminated by Newsfile. Item 4.Summary of Material Change The Company announced the appoint

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission file number: 000-5666

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

BioHarvest Announces Appointment of Sharon Malka to Board of Directors

BioHarvest Announces Appointment of Sharon Malka to Board of Directors   Veteran Technology Leader Brings 25+ Years of Financial and Capital Markets Experience to the Board    Vancouver, British Columbia and Rehovot, Israel – January 22, 2025 - BioHarvest Sciences Inc.

BioHarvest Issues Shareholder Letter and Provides Corporate Update

News Release dated January 8, 2025 BioHarvest Issues Shareholder Letter and Provides Corporate Update   Vancouver, British Columbia and Rehovot, Israel - January 8, 2025 - BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission file number: 000-5666

6-K 1 bhsc6k.htm REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission file number: 000-56663 BIOHARVEST SCIENCES INC. (Exact name of Registrant as specified in its charter) Not applicable (Translation of Registrant’s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission file number: 000-566

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

____________________________________________________________________________ Tate & Lyle and BioHarvest Announce Partnership to Drive the Future of Ingredients through Botanical Synthesis Technology

Tate & Lyle and BioHarvest Announce Partnership to Drive the Future of Ingredients through Botanical Synthesis Technology   New collaboration to pioneer next generation of plant-based ingredients for healthier food and beverages    December 11, 2024 - London, UK and Vancouver, Canada - Tate & Lyle PLC (‘Tate & Lyle’), a world leader in ingredient solutions for healthier and tastier food and beverages, and BioHarvest Sciences (NASDAQ:BHST) (CSE:BHSC) (‘BioHarvest’), leaders in Botanical Synthesis, announce a pioneering new partnership to develop the next-generation of proprietary plant-based molecules to address increasing consumer desire for affordable, nutritious and more sustainable plant-derived food and beverage ingredients.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 000-566

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

BioHarvest Sciences Reports Third Quarter 2024 Financial Results Third Quarter 2024 Revenue Increased 101% Year-over-Year to Over $6.5 Million, Exceeding Management Guidance

News Release dated November 25, 2024 BioHarvest Sciences Reports Third Quarter 2024 Financial Results Third Quarter 2024 Revenue Increased 101% Year-over-Year to Over $6.

BioHarvest Launches VINIA® SuperFood Functional Tea Line Incremental Product Launch Addresses $3.3 Billion North American Functional Tea Market Opportunity with First SuperFood Tea Infused with Piceid Resveratrol

BioHarvest Launches VINIA® SuperFood Functional Tea Line Incremental Product Launch Addresses $3.

Form 52-109FV2 Certification of interim filings - venture issuer basic certificate

Form 52-109FV2 Certification of interim filings - venture issuer basic certificate I, Bar Ditcher, Chief Financial Officer of BioHarvest Sciences Inc.

BioHarvest Sciences Inc. Management’s Discussion and Analysis For the three and nine months ended September 30, 2024 (Expressed in U.S. dollars)

BioHarvest Sciences Inc. Management’s Discussion and Analysis For the three and nine months ended September 30, 2024 (Expressed in U.S. dollars) INTRODUCTION The following Management’s Discussion and Analysis (“MD&A”) for BioHarvest Sciences Inc., together with its wholly owned subsidiaries (“BioHarvest Sciences” or “the Company”) prepared as of November 25, 2024, has been prepared in accordance w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 000-566

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2024 Expressed in U.S. dollars in thousands BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Fin

EX-99.1 2 bhscex991.htm UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three and Nine Months Ended September 30, 2024 Expressed in U.S. dollars in thousands BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three and Nine Months Ended September

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 000-566

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

Form 52-109FV2 Certification of interim filings - venture issuer basic certificate

Form 52-109FV2 Certification of interim filings - venture issuer basic certificate I, Ilan Sobel, Chief Executive Officer of BioHarvest Sciences Inc.

BioHarvest Sciences to Participate in Noble Capital Markets Emerging Growth Conference on December 3, 2024

BioHarvest Sciences to Participate in Noble Capital Markets Emerging Growth Conference on December 3, 2024 Vancouver, British Columbia and Rehovot, Israel – November 21, 2024 – BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 000-566

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

BioHarvest Sciences to Host Third Quarter 2024 Earnings Call on November 25 at 4:30 p.m. Eastern Time

BioHarvest Sciences to Host Third Quarter 2024 Earnings Call on November 25 at 4:30 p.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 000-566

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 000-566

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

NR: 111524-1 CSE:BHSC – FSE:8MV –NASDAQ:BHST BIOHARVEST SCIENCES INC. ANNOUNCES GRANT OF RESTRICTED SHARE UNITS AND STOCK OPTIONS

NR: 111524-1 CSE:BHSC – FSE:8MV –NASDAQ:BHST BIOHARVEST SCIENCES INC. ANNOUNCES GRANT OF RESTRICTED SHARE UNITS AND STOCK OPTIONS VANCOUVER, CANADA, and REHOVOT, ISRAEL, November 15, 2024 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV) announces that it has granted 5,400 Restricted Share Units (“RSUs”) to an employee, with a deemed issuance price of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 000-566

6-K 1 bhsc6k.htm REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC. (Exact name of Registrant as specified in its charter) Not applicable (Translation of Registrant’s

BioHarvest Sciences Begins Trading on the Nasdaq Global Market

BioHarvest Sciences Begins Trading on the Nasdaq Global Market Vancouver, British Columbia and Rehovot, Israel – November 12, 2024 – BioHarvest Sciences Inc.

BioHarvest Sciences Announces Uplisting to the Nasdaq Global Market Common Shares to Begin Trading on Nasdaq on Tuesday, November 12, 2024

BioHarvest Sciences Announces Uplisting to the Nasdaq Global Market Common Shares to Begin Trading on Nasdaq on Tuesday, November 12, 2024 Vancouver, British Columbia and Rehovot, Israel – November 7, 2024 – BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 000-566

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

FORM 51-102F3 MATERIAL CHANGE REPORT

FORM 51-102F3 MATERIAL CHANGE REPORT Item 1.Name and Address of Company BIOHARVEST SCIENCES INC. Suite 1140 – 625 Howe Street Vancouver, BC, V6C 2T6 (the “Company”) Item 2.Date of Material Change November 7, 2024 Item 3.News Release The news release (the “News Release”) was issued and disseminated by Newsfile Corp. on November 7, 2024. Item 4.Summary of Material Change The Company announced that t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission file number: 000-5666

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

FORM 51-102F3 MATERIAL CHANGE REPORT

FORM 51-102F3 MATERIAL CHANGE REPORT Item 1.Name and Address of Company BIOHARVEST SCIENCES INC. Suite 1140 – 625 Howe Street Vancouver, BC, V6C 2T6 (the “Company”) Item 2.Date of Material Change October 28, 2024 Item 3.News Release The news release (the “News Release”) was issued and disseminated on October 28, 2024. Item 4.Summary of Material Change Bar Dichter was appointed as the new Chief Fin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOHARVEST SCIENCES INC. (Exact name of Registran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 BIOHARVEST SCIENCES INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission file number: 000-5666

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

BioHarvest Sciences Appoints Bar Dichter as CFO

BioHarvest Sciences Appoints Bar Dichter as CFO Vancouver, British Columbia and Rehovot, Israel – October 28, 2024 – BioHarvest Sciences Inc.

BioHarvest Sciences Announces Record Preliminary Third Quarter 2024 Financial Results Management Guides Fourth Quarter Revenues to Grow to at Least $7.2 Million USD; Reaffirms Goal to Complete Nasdaq Uplisting by Year-End

BioHarvest Sciences Announces Record Preliminary Third Quarter 2024 Financial Results Management Guides Fourth Quarter Revenues to Grow to at Least $7.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission file number: 000-5666

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

BioHarvest Sciences to Participate in LD Micro Main Event XVII Conference on October 30, 2024

BioHarvest Sciences to Participate in LD Micro Main Event XVII Conference on October 30, 2024 Vancouver, British Columbia and Rehovot, Israel – October 16, 2024 – BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission file number: 000-5666

6-K 1 bhsc6k.htm REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC. (Exact name of Registrant as specified in its charter) Not applicable (Translation of Registrant’s

NR: 200924-1 CSE:BHSC – FSE:8MV – OTC: CNVCF

NR: 200924-1 CSE:BHSC – FSE:8MV – OTC: CNVCF BioHarvest Sciences Reports Director’s Ongoing Key Role Following Resignation from Board Vancouver, British Columbia and Rehovot, Israel – September 20, 2024 – BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission file number: 000-56

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

FORM 51-102F3 MATERIAL CHANGE REPORT

FORM 51-102F3 MATERIAL CHANGE REPORT Item 1.Name and Address of Company BIOHARVEST SCIENCES INC. Suite 1140 – 625 Howe Street Vancouver, BC, V6C 2T6 Item 2.Date of Material Change September 20, 2024 Item 3.News Release The news release was issued on September 20, 2024, disseminated by Newsfile Corp. and filed on www.sedarplus.ca. Item 4.Summary of Material Change BioHarvest Sciences Inc. announced

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission file number: 000-56

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

BioHarvest Sciences to Participate in iAccess Alpha Buyside Best Ideas Conference on September 24-25, 2024

BioHarvest Sciences to Participate in iAccess Alpha Buyside Best Ideas Conference on September 24-25, 2024 Vancouver, British Columbia and Rehovot, Israel – September 12, 2024 – BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission file number: 000-56

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission file number: 000-56

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

FORM 7 MONTHLY PROGRESS REPORT

Monthly Progress Report dated September 5, 2024 FORM 7 MONTHLY PROGRESS REPORT Name of Listed Issuer: BioHarvest Sciences Inc.

BioHarvest Sciences to Present at H.C. Wainwright 26th Annual Global Investment Conference

News Release Dated September 4, 2024 BioHarvest Sciences to Present at H.C. Wainwright 26th Annual Global Investment Conference Vancouver, British Columbia and Rehovot, Israel – September 4 , 2024 - – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) (OTCQB: CNVCF), a company pioneering its patented Botanical Synthesis technology platform, today announced it will participate in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission file number: 000-56

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

BioHarvest Sciences Reports Record Second Quarter 2024 Financial Results Q2 2024 Revenue Increased 119% Year-over-Year to Over $6.0 Million, Exceeding Management Guidance Management Expects Third Quarter 2024 Revenues of at Least $6.5 Million, with a

News Release Dated August 29, 2024 BioHarvest Sciences Reports Record Second Quarter 2024 Financial Results Q2 2024 Revenue Increased 119% Year-over-Year to Over $6.

Form 52-109FV2 Certification of interim filings - venture issuer basic certificate

Certificate - CEO Form 52-109FV2 Certification of interim filings - venture issuer basic certificate I, Ilan Sobel, Chief Executive Officer of BioHarvest Sciences Inc.

BioHarvest Sciences Surpasses USD $1.0 Million in Cumulative Direct Sales of Coffee with VINIA Inside

News Release Dated August 28, 2024 BioHarvest Sciences Surpasses USD $1.0 Million in Cumulative Direct Sales of Coffee with VINIA Inside Vancouver, British Columbia and Rehovot, Israel – August 28 , 2024 - – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) (OTCQB: CNVCF), a company pioneering its patented Botanical Synthesis technology platform, today announced that its VINIA®

Form 52-109FV2 Certification of interim filings - venture issuer basic certificate

Certificate - CFO Form 52-109FV2 Certification of interim filings - venture issuer basic certificate I, Alan Rootenberg, Chief Financial Officer of BioHarvest Sciences Inc.

BioHarvest Sciences Inc. Management’s Discussion and Analysis For the three and six months ended June 30, 2024 (Expressed in U.S. dollars)

Management’s Discussion and Analysis BioHarvest Sciences Inc. Management’s Discussion and Analysis For the three and six months ended June 30, 2024 (Expressed in U.S. dollars) INTRODUCTION The following Management’s Discussion and Analysis (“MD&A”) for BioHarvest Sciences Inc., together with its wholly owned subsidiaries (“BioHarvest Sciences” or the “Company”) prepared as of August 29, 2024, has

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission file number: 000-56663

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial Statements For the Three and Six Months Ended June 30, 2024 Expressed in U.S. dollars in thousands BioHarvest Sciences Inc. Unaudited Interim Condensed Consolidated Financial

Unaudited Interim Condensed Consolidated Financial Statements BioHarvest Sciences Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission file number: 000-56663

Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission file number: 000-56663 BIOHARVEST SCIENCES INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F/A Amendment No. 3 (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F/A Amendment No.

Memorandum of Agreement

Certain portions of this exhibit have been redacted as such portions are not material and the type of Information that the Company treats as private or confident/al.

[Signature Page to Follow]

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F/A Amendment No. 2 (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F/A Amendment No.

ENGLISH TRANSLATION AGREEMENT DATED MARCH 21, 2007 BETWEEN BIOHARVEST LTD. AND THE LICENSOR (IN HEBREW) State of Israel

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

Memorandum of Agreement

Certain portions of this exhibit have been redacted as such portions are not material and the type of Information that the Company treats as private or confident/al.

SUMMARY IN ENGLISH AGREEMENT DATED MARCH 31, 2024 AMONG BIOHARVEST ISRAEL, THE YAVNE NO. 2 LANDLORD AND THE SELLER (IN HEBREW)

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F/A Amendment No. 1 (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F/A Amendment No.

EX-4.4

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

EX-4.2

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

[DESCRIPTION OF PROPERTY REDACTED] [DESCRIPTION OF EQUIPMENT REDACTED] Tripartite Agreement

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

New York • Chicago • San Diego • Aliso Viejo • Austin • Minneapolis • Taipei • Sao Paulo INVESTOR RELATIONS CONSULTING AGREEMENT

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

portions are not material and the type of information that the Company treats as private or confidential. Employment Agreement

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

SUMMARY IN ENGLISH LEASE AGREEMENT DATED MARCH 31, 2024 BETWEEN BIOHARVEST ISRAEL. AND YAVNE LANDLORD NO. 2 (IN HEBREW)

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

[Signature Page to Follow]

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

EX-4.3

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

BIOHARVEST SCIENCES INC. EQUITY INCENTIVE COMPENSATION PLAN Article I ESTABLISHMENT, PURPOSE AND DURATION

BIOHARVEST SCIENCES INC. EQUITY INCENTIVE COMPENSATION PLAN Article I ESTABLISHMENT, PURPOSE AND DURATION 1.1 Establishment of the Plan. The following is the equity incentive compensation plan (the “Plan”) of BioHarvest Sciences Inc. (the “Corporation”), pursuant to which security-based compensation Awards (as defined below) may be granted to Permitted Participants (as defined below). The name of

STOCK OPTION PLAN (As amended and restated on November 9, 2023)

STOCK OPTION PLAN (As amended and restated on November 9, 2023) 1.PURPOSE OF PLAN 1.1Purpose. The purpose of the Stock Option Plan (the “Plan”) of BIOHARVEST SCIENCES INC., a company incorporated under the Business Corporations Act (British Columbia), (the “Company”) is to advance the interests of the Company by encouraging the directors, officers, employees, management company employees and consu

are not material and the type of information that the Company treats as private or confidential.

Certain portions of this exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

Memorandum of Agreement

Certain portions of this exhibit have been redacted as such portions are not material and the type of Information that the Company treats as private or confident/al.

material and the type of information that the Company treats as private or HI-NUTRA BIOSCIENCE LTD.

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

CONSULTING AGREEMENT

Certain portions of this exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

SUMMARY IN ENGLISH AGREEMENT DATED MARCH 31, 2024 AMONG BIOHARVEST ISRAEL, THE YAVNE NO. 2 LANDLORD AND THE SELLER (IN HEBREW)

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☒REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report: For the transition period from to Commission file number: BIOHARVEST SCIENCES INC.

BUSINESS CORPORATIONS ACT BIOHARVEST SCIENCES INC. Table of Contents

Incorporation No. BC0967987 BUSINESS CORPORATIONS ACT ARTICLES OF BIOHARVEST SCIENCES INC. Table of Contents Part 1 – Interpretation2 Part 2 – Shares and Share certificates3 Part 3 – Issue of Shares4 Part 4 – Share Transfers4 Part 5 – Acquisition of Shares5 Part 6 – Borrowing Powers5 Part 7 – General Meetings5 Part 8 – Proceedings at Meetings of Shareholders7 Part 9 – Alterations and Resolutions10

EX-4.2

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

SUBSIDIARIES OF THE COMPANY Subsidiary Jurisdiction of Organization BioHarvest Ltd. Israel BioHarvest Inc. Delaware Superfood Nutraceuticals Inc. Delaware

SUBSIDIARIES OF THE COMPANY Subsidiary Jurisdiction of Organization BioHarvest Ltd. Israel BioHarvest Inc. Delaware Superfood Nutraceuticals Inc. Delaware

[DESCRIPTION OF PROPERTY REDACTED] [DESCRIPTION OF EQUIPMENT REDACTED] Tripartite Agreement

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

EX-1.2

Notice of Articles

DEVELOPMENT AGREEMENT

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

EX-4.4

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

ENGLISH TRANSLATION AGREEMENT DATED MARCH 21, 2007 BETWEEN BIOHARVEST LTD. AND THE LICENSOR (IN HEBREW) [NAME REDACTED]

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

9 Schedule A Bonuses

Certain portions of this exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.

are not material and the type of Information that the Company treats as private or confidential. MANAGEMENT CONSULTING AGREEMENT

Certain portions of this exhibit have been redacted as such portions are not material and the type of Information that the Company treats as private or confidential.

New York • Chicago • San Diego • Aliso Viejo • Austin • Minneapolis • Taipei • Sao Paulo INVESTOR RELATIONS CONSULTING AGREEMENT

Certain portions of the exhibit have been redacted as such portions are not material and the type of information that the Company treats as private or confidential.